DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Benchmark Upgrades Amedisys to Buy, Announces $205 Price Target

Benchmark analyst Bill Sutherland upgrades Amedisys (NASDAQ:AMED) from Hold to Buy and announces $205 price target.

Benzinga · 03/09/2020 12:54

Benchmark analyst Bill Sutherland upgrades Amedisys (NASDAQ:AMED) from Hold to Buy and announces $205 price target.